Therapeutic index improvement of antibody-drug conjugates
The commentary by Colombo and Rich recently published in Cancer Cell provides a timely and comprehensive review of the clinical maximum tolerated doses (MTDs) of antibody−drug conjugates (ADCs) and their corresponding small molecules/chemotherapies. The authors identified similarities between their...
Saved in:
| Main Authors: | Hans-Peter Gerber, Sanjeev Gangwar, Alison Betts |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2023.2230618 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Exploration of the antibody–drug conjugate clinical landscape
by: Heather Maecker, et al.
Published: (2023-12-01) -
Antibody-drug conjugates in cancer therapy: applications and future advances
by: Rou Long, et al.
Published: (2025-05-01) -
Antibody drug conjugates
by: Stalin Bala, et al.
Published: (2020-01-01) -
Advancements in antibody-drug conjugates as cancer therapeutics
by: Jung Yin Fong, et al.
Published: (2025-08-01) -
Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations
by: Miao Wen, et al.
Published: (2025-12-01)